Quality of life in patients with relapsing multiple sclerosis taking intramuscular interferon beta-1a (Avonex®)

被引：0
|
作者：
Hyde, R.
Rudick, R. A.
Foulds, P.
You, X.
机构：
[1] Biogen Idec Int, Zug, Switzerland
[2] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[3] Biogen Idec Inc, Cambridge, MA 02142 USA
来源：
JOURNAL OF NEUROLOGY | 2008年 / 255卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P455
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [31] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    You, Xiaojun
    Scott, Thomas
    Shang, Shulian
    Evilevitch, Vladimir
    Sabetella, Guido
    Werneburg, Brian
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 415 - 415
  • [32] Long-term follow-up of multiple sclerosis patients treated with interferon beta-1a (Avonex®)
    Vermersch, R
    Denève, M
    Waucquier, N
    de Seze, J
    MULTIPLE SCLEROSIS, 2005, 11 : S75 - S75
  • [33] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    Scott, Thomas
    Shang, Shulian
    Castrillo-Viguera, Carmen
    NEUROLOGY, 2017, 88
  • [34] Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study
    Kleinschnitz, Christoph
    Niemczyk, Gabriele
    Rehberg-Weber, Karin
    Wernsdoerfer, Colin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (07): : 15271 - 15286
  • [35] Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): Comparing results of measurements in two different laboratories
    Shahkarami, Mohammad Amir
    Vaziri, Behrouz
    Salami, Shiva
    Harandi, Ali Amini
    Oger, Joel
    JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 388 (1-2) : 46 - 48
  • [36] Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
    Cohan, Stanley L.
    Hendin, Barry A.
    Reder, Anthony T.
    Smoot, Kyle
    Avila, Robin
    Mendoza, Jason P.
    Weinstock-Guttman, Bianca
    CNS DRUGS, 2021, 35 (07) : 743 - 767
  • [37] Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis
    Guijarro, Cristina
    Benito-Leon, Julian
    Bermejo-Pareja, Felix
    NEUROLOGICAL SCIENCES, 2011, 32 (02) : 309 - 311
  • [38] Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex)
    Stanley L. Cohan
    Barry A. Hendin
    Anthony T. Reder
    Kyle Smoot
    Robin Avila
    Jason P. Mendoza
    Bianca Weinstock-Guttman
    CNS Drugs, 2021, 35 : 743 - 767
  • [39] Development of an electronic device for subcutaneous injection of interferon beta-1a in patients with relapsing multiple sclerosis
    Mikol, D.
    Verdun, E.
    Exell, S.
    Devonshire, V.
    MULTIPLE SCLEROSIS, 2010, 16 (10): : 1282 - 1282
  • [40] Subgroup analyses from SENTINEL:: a randomized controlled trial of natalizumab (Tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS)
    Confavreux, C
    Stuart, WH
    Calabresi, PA
    Galetta, SL
    Radue, EW
    Rudick, RA
    Lublin, FD
    Weinstock-Guttman, B
    Wynn, DR
    Lynn, F
    Panzara, MA
    Sandrock, AW
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S72 - S72
12345